37 Editorial on relevance of cardiac toxicity References 1. Van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. [Internet]. 366(22), 2074–84 (2012). Available from: http://www.ncbi.nlm.nih.gov/pubmed/22646630. 2. Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer - A meta-analysis of the randomized trials. Cancer Treat. Rev. 38, 599–604 (2012). 3. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J. Clin. Oncol. [Internet]. 21(18), 3431–9 (2003). Available from: http://www.ncbi.nlm.nih.gov/pubmed/12885835. 4. McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother. Oncol. [Internet]. 100(2), 167–75 (2011). Available from: http://www.ncbi.nlm.nih.gov/pubmed/21752480. 5. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. [Internet]. 368(11), 987–98 (2013). Available from: http://www. ncbi.nlm.nih.gov/pubmed/23484825. 6. Beukema JC, van Luijk P, Widder J, Langendijk J a., Muijs CT. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother. Oncol. [Internet]. 114, 85–90 (2015). Available from: http://linkinghub.elsevier.com/retrieve/pii/S0167814014005428. 7. Stewart F a. Mechanisms and dose-response relationships for radiation-induced cardiovascular disease. Ann. ICRP [Internet]. 41(3-4), 72–9 (2011). Available from: http://www.ncbi.nlm.nih.gov/ pubmed/23089006. 8. Fukada J, Shigematsu N, Takeuchi H. Symptomatic Pericardial Effusion After Chemoradiation Therapy in Esophageal Cancer Patients. Radiat. Oncol. Biol. [Internet]. 87(3), 487–493 (2013). Available from: http://dx.doi.org/10.1016/j.ijrobp.2013.07.008. 9. Konski A, Li T, Christensen M, et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother. Oncol. [Internet]. 104(1), 72–7 (2012). Available from: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=3389132&tool=pmcentrez&rendertype=abstract. 10. Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman K a. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. [Internet]. 83(5), 1580– 1586 (2012). Available from: http://dx.doi.org/10.1016/j.ijrobp.2011.10.053. 11. Ordu AD, Nieder C, Geinitz H, et al. Association Between Radiation Dose and Pathological Complete Response After Preoperative Radiochemotherapy in Esophageal Squamous Cell Cancer. Anticancer Res. 34, 7255–7261 (2014). 12. Welsh J, Gomez D, Palmer MB, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: A dosimetric study. Int. J. Radiat. Oncol. Biol. Phys. 81(5), 1336–1342 (2011). 13. Langendijk J a, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother. Oncol. [Internet]. 107(3), 267–73 (2013). Available from: http://www.ncbi.nlm.nih.gov/ pubmed/23759662. 3
RkJQdWJsaXNoZXIy MTk4NDMw